Clinical trials: Chronic Obstruct Airways Disease
COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure)
A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults
Prevora is an antiseptic medication and dental treatment approved by Health Canada for reducing root decay (cavities) in adults at high risk of dental decay. An antiseptic kills germs and harmful bacteria.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure), Dialysis, Chronic Metabolic Disorder
- Trial name
- NCT06158633
- Testing
- Prevora
- Volunteers
- 30 people
- Sponsor
- CHX Technologies Inc.
Pulmonary Emphysema
Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205907
- Testing
- BLVR Hydrogel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
This clinical trial aims to assess the impact on exercise tolerance and the safety of inhaled nitric oxide in subjects with moderate-to-severe COPD.
- Trial name
- NCT07382258
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Novlead Inc.
Asthma, COPD
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
This was an open-label, multiple-dose, study of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 micrograms (mcg) twice daily (BID) (2 puffs of MF/F MDI 50/5 mcg, administered twice a day…
- Trial name
- NCT00604500
- Testing
- SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
- Volunteers
- 272 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.
- Trial name
- PILASTER (NCT04636801)
- Testing
- Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg
- Where
- 447 sites in United States, Albania and 28 more
- Volunteers
- 4,710 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients
A phase 3 study to evaluate efficacy and safety of HCP1202
- Trial name
- NCT02941679
- Testing
- HCP1202, HGP1011, HCP0910
- Volunteers
- 252 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
COPD
The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD
This is a study examining the effect of inhaled PUL-042 on peak lower respiratory symptoms as measured by subject diary in early stage COPD subjects who are experimentally infected with rhinovirus.
- Trial name
- NCT03794557
- Testing
- Sterile Water Injection, PUL-042 Inhalation Solution
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Pulmotect, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC)…
- Trial name
- NCT01822899
- Testing
- Umeclidinium bromide/Vilanterol, Fluticasone propionate/Salmeterol
- Where
- 78 sites in Czechia, Denmark and 6 more
- Volunteers
- 717 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01513460
- Testing
- NVA237 50µg once daily, Tiotropium 18µg once daily, Flu/Sal
- Where
- 71 sites in Australia, New Zealand
- Volunteers
- 773 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease
Pilot study in 15 stable male subjects with severe-to-very severe Chronic Obstructive Pulmonary Disease (COPD) to evaluate the effects of short term use of the Breathe Technologies noninvasive open ventilation (NIOV) system on…
- Trial name
- NCT01372462
- Testing
- NIOV - Room Air, NIOV - Oxygen, Nasal Cannula Oxygen
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Breathe Technologies, Inc.
COPD, Chronic Obstructive Pulmonary Disease
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for…
- Trial name
- GOLDEN-4 (NCT02347774)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer
- Where
- 45 sites in United States
- Volunteers
- 641 people
- Sponsor
- Sunovion Respiratory Development Inc.
Pulmonary Disease, Chronic Obstructive
Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease
Relatively little information is available about the effects of salmeterol/fluticasone combination and fluticasone alone in COPD patients with a partial reversible pulmonary obstruction.
- Trial name
- NCT00549146
- Testing
- fluticasone propionate/salmeterol 250/50 DISKUS combination product, fluticasone propionate DISKUS 500mcg
- Where
- 17 sites in Netherlands
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
The primary objective of this study is to assess the effect of umeclidinium/vilanterol (UMEC/VI) versus tiotropium/olodaterol (TIO/OLO) in subjects with moderated COPD.
- Trial name
- NCT02799784
- Testing
- UMEC/VI, TIO/OLO, Albuterol/salbutamol
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects
This is an open-label,partially randomized, four-period study in healthy male subjects to assess the bioavailability and pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two…
- Trial name
- NCT02648438
- Testing
- AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe…
- Trial name
- OBERON (NCT05166889)
- Testing
- Tozorakimab
- Where
- 212 sites in United States, Argentina and 19 more
- Volunteers
- 1,132 people
- Sponsor
- AstraZeneca
Lower Respiratory Tract Infection, Acute Bronchitis
Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
The purpose of this study is to validate the diagnostic accuracy of a novel host-response based diagnostic tool for differentiating between bacterial and viral etiologies in adult patients aged 18 years and older with clinical…
- Conditions
- Lower Respiratory Tract Infection, Acute Bronchitis, Pneumonia, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- OBSERVER (NCT03011515)
- Where
- Israel
- Volunteers
- 583 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Pulmonary Disease, Chronic Obstructive
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.
- Trial name
- NCT00676052
- Testing
- GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg
- Where
- 88 sites in United States, Argentina and 12 more
- Volunteers
- 576 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
To compare the efficacy and safety of tiotropium plus formoterol in comparison to salmeterol plus fluticasone in COPD patients.
- Trial name
- NCT00239421
- Testing
- Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule), Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.
- Where
- 56 sites in Austria, Belgium and 6 more
- Volunteers
- 605 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.